The intravenous contrast agents market is projected to grow from USD 11,880.0 million in 2026 to USD 20,485.9 million by 2036, at a CAGR of 5.6%. Iodinated contrast agents will dominate with a 52.0% market share, while CT imaging will lead the applications segment with a 48.0% share.